Work

Abstract 828: ANS03, a novel, orally bioavailable small-molecule type II ROS1/NTRK inhibitor, effectively overcomes clinically relevant ROS1/NTRK resistance mutations and exhibits potent antitumor activity in preclinical tumor models

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-828

Authors: Gong Li, Alexander Drilon, Shengxiang Ren, Peilong Zhang, Xiangqiu Li, Linna Li, Ruiya Zhang, Wenli Lan, Di Han, Weizhe Xue, Peipei Yang, Shutan Liao, Kevin Schaab, Brendan Putz, Hepeng Shi

Institutions: Beijing Avistone Biotechnology Co., Ltd. (China), Memorial Sloan Kettering Cancer Center, Shanghai Pulmonary Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409690125

Cites:

Cited by:

Related to: 10